Peripheral Artery Disease

Higher doses of statins may more effectively prevent adverse clinical outcomes in PAD.

A meta-analysis of COMPASS and VOYAGER compared low-dose rivaroxaban and aspirin vs aspirin alone across a broad spectrum of patients with PAD.

A prospective, cross-sectional study examined the relationship between symptomatic and asymptomatic PAD with risk for abdominal aortic aneurysm.

Investigators evaluated outcomes of a first-line hybrid approach in patients with chronic limb-threatening ischemia to determine possible predictors of loss of primary patency and limb clinical improvement.

This review examines the current guidance and issues related to lipid optimization of patients with peripheral arterial disease (PAD).

Researchers found an additive benefit with rivaroxaban in combination with aspirin in terms of event reduction.

SAFE-PAD evaluated the real-world safety of femoropopliteal artery revascularization using drug-coated vs non-drug-coated devices.